J Cancer 2014; 5(5):344-350. doi:10.7150/jca.9021

Research Paper

Enhancement of Aerosol Cisplatin Chemotherapy with Gene Therapy Expressing ABC10 protein in Respiratory System

Wolfgang Hohenforst-Schmidt1, Paul Zarogoulidis2✉, Bernd Linsmeier3, Ioannis Kioumis2, Qiang Li4, Haidong Huang4, Despoina Sachpatzidou5, Sofia Lampaki2, John Organtzis2, Kalliopi Domvri2, Leonidas Sakkas6, George A. Zachariadis7, Konstantinos N. Archontas7, Anastasios Kallianos8, Aggeliki Rapti8, Lonny Yarmus9, Konstantinos Zarogoulidis2, Johannes Brachmann1

1. II Medical Department, ``Coburg`` Regional Clinic, University of Wuerzburg, Coburg, Germany
2. Pulmonary Department-Oncology Unit, ``G. Papanikolaou`` General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
3. Department of Thoracic Surgery, Medinos Clinic Sonneberg, Sonneberg, Germany
4. Department of Respiratory Diseases, Changhai Hospital/First Affiliated Hospital of the Second Military Medical University, Shanghai, China
5. Experimental Animal Laboratory, ``Theiagenio`` Anticancer Hospital, Thessaloniki, Greece
6. Pathology Department, ``G. Papanikolaou`` General Hospital, Thessaloniki, Greece
7. Laboratory of Analytical Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, Thessaloniki, Greece
8. Pulmonary Department, ``Sotiria`` Hospital of Chest Diseases, Athens, Greece
9. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, U.S.A.


Inhaled therapy for lung cancer is a local form of treatment. Currently inhaled non-specific cytotoxic agents have been evaluated as a future treatment for local disease control and distant metastasis control. There are few information regarding the influence of local transporters and gene expression of the respiratory epithelium to the absorption of administered drugs. In the current work we used adenoviral-type 5(dE1/E3) (Cytomegalovirus promoter) with human ABCA10 transgene (Ad-h-ABCA10) purchased from Vector Labs® in order to investigate whether gene therapy can be used as a pre-treatment to enhance the efficiency of inhaled cisplatin. We included the following groups to our work: a) control, b) aerosol vector, c) aerosol vector plus cisplatin, d) aerosol cisplatin, e) intratumoral cisplatin administration, f) intratumoral vector plus cisplatin administration. The results indicate that the aerosol cisplatin group had a long term survival with the intratumoral cisplatin group following. The enhancement of the ABCA family locally to the respiratory system prior to the aerosol cisplatin administration can be used safely and efficiently. Future treatment design of local therapies should include the investigation of local transporters and genes.

Keywords: ATP, ABC10, lung cancer, gene therapy, chemotherapy, aerosol.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Hohenforst-Schmidt W, Zarogoulidis P, Linsmeier B, Kioumis I, Li Q, Huang H, Sachpatzidou D, Lampaki S, Organtzis J, Domvri K, Sakkas L, Zachariadis GA, Archontas KN, Kallianos A, Rapti A, Yarmus L, Zarogoulidis K, Brachmann J. Enhancement of Aerosol Cisplatin Chemotherapy with Gene Therapy Expressing ABC10 protein in Respiratory System. J Cancer 2014; 5(5):344-350. doi:10.7150/jca.9021. Available from http://www.jcancer.org/v05p0344.htm